PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsCommentDirect-to-consumer genetic tests — more than just a question of health

BioNews

Direct-to-consumer genetic tests — more than just a question of health

Published 14 December 2015 posted in Comment and appears in BioNews 832

Author

Andelka Phillips

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

There is now a huge range of direct-to-consumer genetic tests on the market, but the public ought to be wary of what exactly they are agreeing to when they sign up for these services...

There is now a huge range of direct-to-consumer (DTC) genetic tests on the market. A distinction is often made between tests offered for health purposes and so-called 'recreational genomics'. Examples include ancestry testing or tests for traits such as whether you find Brussels sprouts bitter, but companies now also offer paternity tests and tests for matchmaking purposes, detecting infidelity, or whether a child is likely to have a particular talent. Consumers should be cautious about these. While some health tests may be useful, many tests for other purposes are not well validated, and it is sometimes questionable what in fact you are buying. Increasingly, companies that began offering tests for one purpose (perhaps recreational) are beginning to offer tests for other purposes. Consequently, what these companies are doing with consumers' sequenced genetic data and other personal data deserves more scrutiny. Can consumers really be said to have given their informed consent in this context? This is debatable, as is the enforceability of some of the contracts that customers are entering into.

As of 19 November 2015, 248 companies were identified offering some form of DNA test online within the last four years. I analysed 71 contracts used by DTC companies offering tests for health purposes (these often appear on websites as terms of use or terms of service). Significantly, I found that companies often include clauses allowing unilateral alteration of terms, and they may deem consent or acceptance of altered terms simply through the continued use of their website. Such clauses are particularly concerning because they allow for significant changes to companies' policies on use, storage, and sharing of data, without consumers being directly notified. In the UK, I hope that the new Competition & Markets Authority might be able to contribute to improving these contracts by preventing the use of certain terms, which might be deemed unfair.

Among these 248 companies, there are some you may have heard of – 23andMe, deCODEme, DNAFit, AncestryDNA, FamilyTreeDNA. Then there are others that you might not have come across, like Shecheated, Test Infidelity, GenePartner, Instant Chemistry or Who'z the Daddy? In my view, the FDA and regulators in other countries need to take action to protect consumers. Ideally, there should be industry-specific legislation that is consistently adhered to. The FDA recently sent warning letters to three companies, but there are more out there (see BioNews 828).

After the FDA's previous warning letter to 23andMe in November 2013 (see BioNews 733), it did cease offering health tests to its US customers, and its new US offerings are limited to carrier testing. However, it continues to offer health testing, including drug-response tests, through its UK and Canadian websites (see BioNews 783).

As many companies are located in the USA, the FDA's renewed regulatory interest is timely, but there are more companies out there. Also, while regulation of health-related tests is very important, we also need to regulate those companies offering non-health-related tests, which means that consumer regulators also need to take action (eg. UK's Competition & Markets Authority and the US FTC). However, regulators often have limited resources, so consumers need to be more aware of what's out there and how to protect themselves.

There is a real need for consumer education and increased awareness of the respective risks, benefits and limitations of these tests. Analysis of these contracts, together with examination of DTC website content, also shows that there is a need for companies to be more transparent. Often, marketing claims made on websites are at odds with the actual terms contained in DTC contracts. Companies offering services to EU consumers ought to comply with European Data Protection law and, at present, this is often not the case. Privacy policies also are not generally tailored to the nature of the services offered. Often they focus on the collection of personal data through cookies, rather than what companies are doing with consumers' actual genetic data once it is sequenced.

Companies providing tests for health purposes as well as some ancestry testing companies are generally at the better end of the spectrum of DTC services on offer and they engage in more responsible business practices. However, many other services ought to be viewed with scepticism, and consumers ought to be wary when considering them. These services include: testing for a child's 'talents'; testing for athletic ability; 'peace of mind' or non-legal paternity tests; DNA-based dating websites; and 'infidelity' tests. Companies that offer infidelity testing services often encourage consumers to send in DNA samples of dubious quality, belonging to third parties and without their consent.

When considering purchasing any DNA test online, I urge you to read the privacy policy and the contract. You need to know what is going to be done with your sequenced DNA. Stored, sequenced DNA identifies individuals and their families so, if you are concerned about long-term protection of your privacy, this is essential. Be aware that, since most DTC companies rely on self-sample collection, there is a risk of sample contamination through a consumer's inexperience. You should also bear in mind that most companies do not offer whole-genome or whole-exome scans, which means that the value of test results on a personal level may be limited.

Moreover, consumers need to be aware that, increasingly, companies are offering testing for more than one purpose. It is also very common for companies offering paternity tests to market infidelity tests. Increasingly too, ancestry testing companies are moving into health testing and health research. This means that you should consider whether you would be comfortable with buying an ancestry test, but then having your stored data used for other purposes.

In the long term, specific regulation of this industry is needed, and academics need to contribute to consumer education about the industry. In the short term, companies need to improve their contracts and increase transparency. If consumers were to actually read these contracts, they might notice the discrepancies with the claims on the website, and they might legitimately wonder what exactly they are buying.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
20 November 2017 • 2 minutes read

FDA to streamline path for direct-to-consumer genetic testing

by Jamie Rickman

The US Food and Drugs Administration has further deregulated direct-to-consumer genetic health risk tests, meaning that some will be approved for market without a pre-market review...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Comment
11 May 2016 • 3 minutes read

Lab in a lunch box

by Craig Macpherson

The development of a portable DNA laboratory for professionals and enthusiasts raises questions about how regulations can possibly protect consumers in this rapidly developing field...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
30 March 2016 • 3 minutes read

Sure Genomics offers direct-to-consumer whole-genome sequencing

by Kulraj Singh Bhangra

US start-up company Sure Genomics has launched the first whole-genome testing service available directly to consumers, for a cost of $2500...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
30 March 2016 • 2 minutes read

DNA testing has 'no impact on lifestyle choices'

by Ryan Ross

A recent study has suggested that genetic tests to assess the risk of diseases like diabetes and lung cancer do little to motivate people to change their behaviour...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
11 March 2016 • 3 minutes read

Genetics company launches huge open-access database

by Isobel Steer

Genetic-testing company Ambry Genetics has launched a huge database of cancer-patient genetics, freely available to the public...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
16 November 2015 • 2 minutes read

FDA warns three US firms over direct-to-consumer genetic testing

by Dr Lone Hørlyck

The US Food and Drug Administration has sent warning letters to three gene-testing companies over the marketing and selling of what it claims are direct-to-consumer gene testing products without its approval...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Comment
23 February 2015 • 3 minutes read

The 23andMe experience - a lot of knowledge is of little help?

by Alison Lashwood

The 23andMe test and other similar direct-to-consumer genetic tests are likely here to stay. Those in favour see them as a way of engaging the public with science and making it fun, but there are problematic aspects, too...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Reviews
15 January 2013 • 3 minutes read

Report Review: Consumer Genetic Testing

by Ruth Saunders

Last week the Parliamentary Office of Science and Technology (POST) released a POST Note - a guide for MPs and other parliamentarians on science and technology issues - on consumer genetic testing...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Reviews
19 November 2012 • 4 minutes read

Event Review: The Age of Personalised Medicine - Genes, Privacy and Discrimination

by Rebecca Hill

'The age of personalised medicine: genes, privacy and discrimination?' was the last in BioCentre's 2010/2011 symposium series 'Revolution, Regulation and Responsibilities', and promised to 'appraise current developments and consider the current legal and regulatory position for their use before taking time to reflect and assess the future impact on society'...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Aspirin is no wonder drug for fertility

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Recent
4 July 2022 • 4 minutes read

Widening the debate about direct-to-consumer genetic testing and donor conception

4 July 2022 • 3 minutes read

Join PET and Genomics England to celebrate the 200th birthday of Gregor Mendel

27 June 2022 • 4 minutes read

Thirty years of PET: our 'Fertility, Genomics and Embryo Research' report

27 June 2022 • 5 minutes read

Children's rights and donor conception: What next?

20 June 2022 • 4 minutes read

The problems with lifting donor anonymity earlier

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856